5 Most Promising Long-Term Stocks According to Analysts

In this piece, we will take a look at the five most promising long-term stocks according to analysts. If you want a deep dive into long term investing, then check out 16 Most Promising Long-Term Stocks According to Analysts.

5. Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)

Average Analyst Share Price Target Percentage Upside: 82.48%

Average Share Price Target: $20

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) is a biotechnology company developing treatments for nervous system disorders and other ailments. The firm has beaten analyst EPS estimates in three out of its four latest quarters and the shares are rated Strong Buy on average.

During Q3 2023, 19 out of the 910 hedge funds surveyed by Insider Monkey had bought a stake in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). The firm’s biggest investor in our database is Aaron Cowen’s Suvretta Capital Management through its $41.8 million stake.

4. NET Power Inc. (NYSE:NPWR)

Average Analyst Share Price Target Percentage Upside: 84.91%

Average Share Price Target: $19.6

NET Power Inc. (NYSE:NPWR) is a clean energy company headquartered in Durham, North Carolina. The firm scored a win in December 2023 when it signed an agreement to supply heat exchangers to another firm.

By the end of this year’s third quarter, 19 out of the 910 hedge funds tracked by Insider Monkey had held a stake in NET Power Inc. (NYSE:NPWR).

3. Valneva SE (NASDAQ:VALN)

Average Analyst Share Price Target Percentage Upside: 96.71%

Average Share Price Target: $20.32

Valneva SE (NASDAQ:VALN) is a French biotechnology company developing treatments for diarrhea, Lyme disease, and other ailments. Its Lyme disease trial is moving fast these days, and in partnership with Pfizer, Valneva SE (NASDAQ:VALN) finished phase three enrollments in December 2023.

During 2023’s September quarter, just one out of the 910 hedge funds part of Insider Monkey’s database were Valneva SE (NASDAQ:VALN)’s shareholders. This lone investor was Benjamin A. Smith’s Laurion Capital Management as it owns $295,000 worth of shares.

2. Evolus, Inc. (NASDAQ:EOLS)

Average Analyst Share Price Target Percentage Upside: 97.76%

Average Share Price Target: $20.29

Evolus, Inc. (NASDAQ:EOLS) is a medical company that specializes in selling products used in aesthetics and beauty applications. Its shares are rated Strong Buy on average and the average share price target is $20.29.

For their third quarter of 2023 shareholdings, 23 out of the 910 hedge funds covered by Insider Monkey had held a stake in the company. Evolus, Inc. (NASDAQ:EOLS)’s largest hedge fund investor is Timothy P. Lynch’s Stonepine Capital due to its $47.3 million stake.

1. Relay Therapeutics, Inc. (NASDAQ:RLAY)

Average Analyst Share Price Target Percentage Upside: 98.23%

Average Share Price Target: $22.40

Relay Therapeutics, Inc. (NASDAQ:RLAY) is a biotechnology company developing treatments for several different tumors. It is also the only firm on our list that has a collaboration with billionaire D. E. Shaw’s research firm to develop drugs.

As of Q3 2023 end, 27 out of the 910 hedge funds tracked by Insider Monkey had invested in Relay Therapeutics, Inc. (NASDAQ:RLAY). Eli Casdin’s Casdin Capital was the biggest stakeholder through its $58.2 million investment.

Disclosure: None. You can also take a look at 25 Cities With The Hottest Guys In The World and 12 Best Stocks to Buy for an 18 Year Old.

Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.